What actually changed?
A cell behaving differently, a hormone rising and a person avoiding a heart attack are different results. We read a claim by asking what researchers measured, who they studied and how they gave the substance.
That's a useful check when a headline sounds broader than its source. A blood test can tell us something real without showing that someone feels better. A careful study can still leave a big question unanswered.
Animals or people?
For BPC-157, the gap is mainly between animal healing and human recovery. A research review describes a lot of animal work beside very little human evidence. That leaves a reason to investigate, rather than a reliable prediction for an injured person.
A health outcome or a hormone reading?
Semaglutide has large human trials. One heart-outcomes trial found fewer serious cardiovascular events. Its participants already had cardiovascular disease and overweight or obesity, without diabetes. A strong result still belongs to the people and question studied.
Ipamorelin raised growth hormone in human research. But a trial after bowel surgery didn't show a clear benefit for its main recovery measure: tolerating a meal sooner. A hormone response didn't settle that practical question.
A marker or a broader benefit?
For NAD+, precursor supplements can raise blood levels. Precursors are substances the body uses to make NAD+. A review of human studies found limited evidence of health benefits. Higher levels don't establish longer life.
For GHK-Cu, the way it's used is central. A review of skin research discusses topical use, meaning application to skin. Those findings can't establish the safety or benefit of an injection.
Which country's answer?
Study results don't establish legal access. The US regulatory information here doesn't confirm Canadian authorization or a local service. The references help you return to the source and check what it actually covers.